THE UNITED REPUBLIC OF TANZANIA

MINISTRY OF HEALTH

TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

PUBLIC ASSESSMENT REPORT FOR XYLOFACT (XYLOMETAZOLINE HYDROCHLORIDE 0.1% W/W) NASAL DROPS

Version number 1.0
21 August 2023

TMDA Headquarters, Plot No. 56/1, Block E, Kisasa B Centre, Hombolo Road, P. O. Box 1253, Dodoma – Tanzania, Telephone: +255 (26) 2961989/2061990/+255 (22) 2450512/2450751/2452108, Email: info@tmda.og.tz, Website: **www.tmda.go.tz**

Toll free: 0800110084

1. Introduction

XYLOFACT is a colourless to almost colourless clear solution filled in 20 ml white plastic LDPE Squeeze bottle contains Xylometazoline HCl 0.1% w/w per each mL. Xylometazoline is a sympathomimetic agent acting on alpha-adrenergic receptors in the nasal mucosa. Administered in the nose, it constricts the nasal blood vessels, thereby decongesting the mucosa of the nose and neighbouring regions of the pharynx. This decongests nasal passages and enables patients suffering from blocked nose to breathe more easily through the nose. XYLOFACT is approved in Tanzania for use in adults and adolescents over 12 years of age.

1.1 Product details

Registration number	TAN 23 H 0253
Brand name	XYLOFACT
Generic name, strength, and form	Each ml contains Xylometazoline HCl 0.1% w/w
ATC classification	R01A A07 – decongestants for topical use, sympathomimetics, plain
Distribution category	POM
Country of origin	India
Associated product	N/A
Marketing Authorization Holder	Biodeal Pharmaceuticals Pvt. Ltd Nalagarh- Ropar Road, Village-Sainimajra, Nalagarh, India.
Local Technical Representative	Generics & Specialities Ltd 2nd Floor, Zahra Arcade, Mindu Street, P.O Box 1469, Dar es Salaam, Tanzania

1.2 Assessment procedure

The application for registration of XYLOFACT was submitted in 2021. The product underwent full assessment. Assessment was completed in 3 (three) rounds of evaluation and the product was registered on 01 June 2023.

1.3 Information for users

Visual description of the finished product	Colourless to almost colourless clear solution filled in 20 ml white plastic LDPE Squeeze bottle
Primary packing material	20 ml white plastic LDPE Squeeze bottle
Secondary packing materials	A printed carton box
Shelf-life and storage condition	36 months, Do not above 30°C. Protect from light.
Route of administration	Nasal
Therapeutic indications	For the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever), sinusitis

2. Labelling and product information

Summary of product characteristics
The SmPC included all the relevant information to ensure correct and safe use of the medicine by healthcare providers. The complete SmPC can be accessed here.

Package insert/leaflet
The package insert is confirmed to be derived from the SmPC and contains sufficient data for the end user. Since the product is POM, the package insert contains full prescribing information as per SmPC.

Container labels
The product label information is presented in English. Details in the secondary pack label include:
Brand name: XYLOFACT

Composition: Each ml contains Xylometazoline HCl 0.1% w/w

Pack size: 1 bottle

Manufacturing details: batch number, manufacturing date, and expiry date

Storage conditions: Do not above 30°C. Protect from light

Manufacturer address: physical address of release site

Unique identifier: Not applicable

Special warnings/precautions or instructions for use: See enclosed leaflet

The details of the primary pack include:

Brand name and strength: XYLOFACT

Manufacturing details: batch number, manufacturing date and expiry date

Name of manufacturer: Biodeal Pharmaceuticals Pvt. Ltd

The content of the primary and secondary labels was aligned to the requirements of the Part V of the Compendium: Guidelines on Format and Content of Product Labels for Medicinal products. The label contains sufficient information for proper identification of the medicine and post marketing follow up of the product.

Mock labels are appended as annex I.

3. Scientific discussion

Quality of Active Pharmaceutical Ingredient

Information on the quality of the API was submitted in form of DMF.

Xylometazoline HCl

General Information

Xylometazoline HCl API is compendia in USP, Ph.Eur., and BP.

Molecular formula: $C_{16}H_{25}ClN_2$

Chemical name:

2-(4-tert.-butyl-2,6-dimethylbenzyl)-2-imidazoline monohydrochloride

Structure:



General properties

Xylometazoline hydrochloride is white or almost white, crystalline powder freely soluble in water, in ethanol (96 per cent) and in methanol.

The polymorphism is not reported for this API so far. Nonetheless, this is not considered important as the active substance is present in solution in the finished product. The active is present in the drug product dissolved in water, hence the polymorphic form and particle size distribution are not considered as critical quality aspects.

Manufacture

Xylometazoline hydrochloride API manufacturer is CTX Lifesciences Pvt. Ltd, Add - Block No: 251-252, Sachin- Magdalla Road GIDC Sachin,Surat – 394 230 Gujarat, India. The manufacturing complies with GMP requirements as evidenced by the GMP certificate issued by the Food & Drugs Control Administration, Gujarat, India. Xylometazoline hydrochloride API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

Specifications

The API specifications were set as per BP standards and ICHQ3A. The parameters monitored during quality control are: Description, solubility, identification, appearance of the solution,

acidity/alkalinity, sulphated ash, LOD, related substances, residual solvents, bulk density, and sieve test. Compliance to these specifications were established via batch analysis data and stability studies.

Stability and container closure system

The re-test period of Xylometazoline hydrochloride API is 72 months when packed in transparent Low-Density Polythene (LDPE) bags with storage condition 'Should be stored Below 25ºC'.

Quality of the Finished Pharmaceutical Product

Formulation

XYLOFACT is a colourless to almost colourless clear solution filled in 20 ml white plastic LDPE Squeeze bottle.

XYLOFACT contains the Xylometazoline hydrochloride, and other ingredients listed here after: disodium edetate, sodium chloride, sodium dihydrogen phosphate dihydrate, sodium phosphate, benzalkonium chloride, distilled water. The quantities of all ingredients are confirmed to be in line with the recommendations of Handbook of Pharmaceutical Excipients, 8th Edition in terms of function and quantities.

Manufacture

The finished product manufacturer is Biodeal Pharmaceuticals Pvt. Ltd, Vill. Saini Majra, Nalagarh-Ropar Road, Nalagarh, Dist Solan 174101 HP, India. The compliance of the sites to TMDA GMP standards was confirmed through site inspection on 24, January, 2022.

Specifications

The FPP is compendia. The manufacturer controls the quality of the finished product as per BP and ICH requirements. The parameters monitored during quality control are: visual description, identification of API, net content, pH, weight per ml, preservative content, related substances, assay, and microbiological quality. Compliance to the standard was established using batch analysis data and stability data.

Stability and container closure system

Stability studies were conducted on three (3) batches of the finished product stored at 30 ± 2°C & RH: 35%RH± 5 % for 36 months and 40± 2°C & RH: 25% for 6 months. Based on the stability data presented, the approved shelf-life is 36 months when stored in polypropylene infusion bottle with storage condition 'Do not above 30°C. Protect from light'.

Safety and efficacy information

XYLOFACT nasal drops is a solution for nasal drop formulation and therefore fulfils the exemption as the product is prepared as aqueous solution and containing the same active pharmaceutical ingredient in the same concentration as currently registered products and which are administered by the same route. The quantitative composition of XYLOFACT nasal drops is entirely the same as the reference products in the market. Therefore, it may be considered as therapeutic equivalent, with the same efficacy/safety profile as known for the active substance of the reference medicinal product. The current product can be used instead of its reference product

4. Benefit-Risk Assessment and Conclusion

On basis of the data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. XYLOFACT nasal drops is recommended for registration.

5. Post-approval updates

Variation applications

Reference number	Date submitted	Change requested	Recommendation	Granting date

Feedback from pharmacovigilance, post marketing surveillance and enforcement activities

Type of feedback	Impact	Response

Re-registration applications

Application for renewal of registration was submitted on <DDMMYYYY>. The application was finalized in <number> rounds of evaluation. The product was confirmed to still be compliant to the standards of quality, safety and efficacy, hence registration was renewed on <DDMMYYYY>.

PART 5: CHANGE HISTORY

Version number	Date	Description of update	Section(s) Modified	Approval date

Annex I: Mock up labels;

Primary pack label;



Label Size:30x37mm (Front)



Label Size:0x37mm (Back)

Secondary pack label;